在帕金森病的免疫基α-synuclein试验的更新
Maha Alfaidi1, Roger A Barker2,3,4,5, Wei-Li Kuan5
1John Van Geest Centre for Brain Repair and Department of Clinical Neuroscience, University of Cambridge, Cambridge, CB2 0PY, UK. m.alfaidi2@gmail.com.
Journal of neurology
|December 12, 2024
概括
针对alpha-synuclein (α-syn) 聚合的治疗策略在帕金森病 (PD) 中表现有前途. 使用疫苗和抗体清除α-syn病理的临床试验正在进行中,但在有效性和试验完成方面面临挑战.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 涉及多巴胺能神经元的逐渐丧失.
- 阿尔法-同核素 (α-syn) 聚合到莱维体中是PD病理学的标志.
- 准α-syn聚合物是PD的关键治疗策略.
研究的目的:
- 审查针对PD中α-syn的疫苗和单克隆抗体最近的临床试验.
- 分析针对α-syn.的积极和被动免疫策略.
- 确定α-syn向PD疗法的挑战和未来方向.
主要方法:
- 对α-syn向疗法的临床试验数据的全面分析.
- 治疗方法分为主动免疫 (疫苗) 和被动免疫 (单克隆抗体).
- 包括UB-312,PD01A,PD03A,ACI-7104.056,Prasinezumab,Cinpanemab,MEDI1341和Lu AF82422在内的特定药物的评估.
主要成果:
- 一些针对α-syn的活性免疫 (UB-312,AFFITOPE PD01A,PD03A,ACI-7104.056) 和被动免疫 (Prasinezumab,Cinpanemab,MEDI1341,Lu AF82422) 疗法已经在临床试验中进行了研究.
- 一些试验在准α-syn病理方面显示出有希望的结果.
- 跨研究观察到包括可变疗效和试验中止在内的挑战.
结论:
- 向α-syn代表了帕金森病的重要治疗途径.
- 尽管有前临床和早期临床数据充满希望,但在开发有效的α-syn向疗法方面仍然存在重大挑战.
- 需要进一步的研究来克服有效性和安全性的障碍,以推进PD的疾病修饰治疗.
更多相关视频
14:45Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
5.9K
10:03Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
10.5K
相关概念视频
Parkinson's Disease: Overview
479
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
479
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Parkinson's Disease: Treatment
219
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
219
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
